MH
GSK icon

Mark Hillman’s GSK GSK Stock Holding History

Mark Hillman’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.84M Sell
92,383
-5,049
-5% -$267K 3.51% 7
2026
Q1 		$5.38M Sell
97,432
-16,904
-15% -$916K 3.73% 4
2025
Q4 		$5.61M Sell
114,336
-27,443
-19% -$1.28M 3.53% 5
2025
Q3 		$6.12M Sell
141,779
-10,820
-7% -$423K 3.56% 6
2025
Q2 		$5.86M Sell
152,599
-12,544
-8% -$479K 3.2% 10
2025
Q1 		$6.4M Sell
165,143
-66,008
-29% -$2.42M 3.15% 8
2024
Q4 		$7.82M Buy
231,151
+34,255
+17% +$1.23M 2.9% 14
2024
Q3 		$8.05M Buy
196,896
+1,770
+0.9% +$72.4K 2.76% 16
2024
Q2 		$7.51M Sell
195,126
-38,360
-16% -$1.61M 2.65% 16
2024
Q1 		$10M Buy
233,486
+100
+0% +$4.12K 3.22% 6
2023
Q4 		$8.65M Buy
233,386
+522
+0.2% +$18.7K 2.99% 12
2023
Q3 		$8.44M Sell
232,864
-1,817
-0.8% -$64.5K 3.25% 5
2023
Q2 		$8.36M Sell
234,681
-2,735
-1% -$98.1K 2.95% 13
2023
Q1 		$8.45M Sell
237,416
-463
-0.2% -$16.2K 3.2% 8
2022
Q4 		$8.36M Sell
237,879
-6,099
-2% -$203K 3.28% 9
2022
Q3 		$7.18M Buy
243,978
+54,511
+29% +$2.07M 2.98% 11
2022
Q2 		$10.3M Buy
189,467
+916
+0.5% +$50.6K 3.75% 4
2022
Q1 		$10.3M Buy
188,551
+2,072
+1% +$113K 3.26% 2
2021
Q4 		$10.3M Sell
186,479
-6,942
-4% -$361K 3.53% 5
2021
Q3 		$9.24M Buy
193,421
+6,561
+4% +$330K 3.24% 12
2021
Q2 		$9.3M Buy
186,860
+1,208
+0.7% +$58K 3.54% 8
2021
Q1 		$8.28M Buy
185,652
+181,156
+4,029% +$8.22M 3.63% 6
2020
Q4 		$207K Buy
+4,496
New +$207K 0.11% 44

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Mark Hillman's GSK Position: Q2 2026 in Review

Mark Hillman reduced its GSK (GSK) stake by 5.2% in Q2 2026, selling an estimated $267K and leaving 92,383 shares worth $4.84M. The position accounts for 3.51% of the portfolio, ranked #7.

Mark Hillman first reported a position in GSK in Q4 2020 and has held it in 23 quarters since. The position peaked at $10.3M in Q2 2022. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Mark Hillman held 92,383 shares of GSK worth $4.84M as of Q2 2026.
  • Mark Hillman sold 5,049 GSK shares in Q2 2026, an estimated $267K.
  • GSK made up 3.51% of Mark Hillman's portfolio in Q2 2026, its #7 holding.
  • Mark Hillman first reported a position in GSK in Q4 2020 and has held it in 23 quarters since.
  • Mark Hillman's GSK position peaked at $10.3M in Q2 2022.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Hillman Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.